ECOR electroCore, Inc.
$8.40+16.18%
Last close: · regular session · Last 60 sessions
After-hours $8.33 -0.83% ·
ECOR dilution and offerings
S-3 shelf filed Oct 2025: it registers shares the company can sell later.
- Float
- 5.9M
- Shelf
- S-3
- Last filing
- 8-K · Nov 4, 2026
Latest SEC filings for ECOR
| 8-K | Current report | |
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| 8-K | Current report | |
| 10-Q | Quarterly report | |
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| D | ||
| S-8 | Employee stock plan | |
| 8-K | Current report |
Dilution today: new offering filings and reverse splits
Active shelf registration (S-3, Oct 2025). Float: 5.9M shares. Latest SEC filing: 8-K on Nov 4, 2026. ECOR closed at $8.40 (+16.18%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ECOR in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
- Exchange: NASDAQ
- Employees: 73
- Website: https://www.electrocore.com
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Latest ECOR news
- ElectroCore outlines 30% to 40% 2027 revenue growth while targeting positive adjusted EBITDA by end of 2027 Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.